Post job

Verrica Pharmaceuticals's revenue is $7.6 million.

What is Verrica Pharmaceuticals's revenue?

Verrica Pharmaceuticals's annual revenue is $7.6M. Zippia's data science team found the following key financial metrics about Verrica Pharmaceuticals after extensive research and analysis.
  • Verrica Pharmaceuticals's revenue growth from 2021 to 2024 is -36.95%.
  • Verrica Pharmaceuticals has 45 employees, and the revenue per employee ratio is $168,133.
  • Verrica Pharmaceuticals's peak quarterly revenue was $12.0M in 2021(q1).
  • Verrica Pharmaceuticals peak revenue was $12.0M in 2021.
  • Verrica Pharmaceuticals annual revenue for 2023 was 5.1M, -43.27% growth from 2022.
  • Verrica Pharmaceuticals annual revenue for 2024 was 7.6M, 47.66% growth from 2023.

On this page

Most recent quarter revenue
$344,000 (Q4'2024)
Company most recent quarter revenue
Peak revenue
$12.0M (2021)
Company peak revenue
Revenue / employee
$168,133
Company revenue / employee

Zippia finds jobs where you're a top candidate and applies on your behalf.

Floating question marks illustration
Most recent quarter revenue
$344,000 (Q4'2024)
Company most recent quarter revenue
Peak revenue
$12.0M (2021)
Company peak revenue
Revenue / employee
$168,133
Company revenue / employee

Verrica Pharmaceuticals historical revenue

Verrica Pharmaceuticals's peak revenue was $12.0M in 2021. The peak quarterly revenue was $12.0M in 2021(q1).

Verrica Pharmaceuticals's revenue increased from $12.0m in 2021 to $7.6M currently. That's a -36.95% change in annual revenue.

Verrica Pharmaceuticals annual revenue

$12M
$10M
$7M
$5M
$2M
$0
2021
2022
2023
2024

Verrica Pharmaceuticals annual revenue over time

Fiscal year / yearVerrica Pharmaceuticals revenue
2021$12.0M
2022$9.0M
2023$5.1M
2024$7.6M

Rate Verrica Pharmaceuticals' financial transparency

Zippia waving zebra

Verrica Pharmaceuticals annual growth

Verrica Pharmaceuticals saw the greatest revenue growth in 2022, when revenue increased by -24.73%.

Verrica Pharmaceuticals had the lowest revenue growth in 2022, when revenue changed by -24.73%.

Verrica Pharmaceuticals annual growth rate over time

YearVerrica Pharmaceuticals growth
2022
-25%
2023
-43%
2024
48%

Verrica Pharmaceuticals quarterly revenue over time

  • Q1
  • Q2
  • Q3
  • Q4
$12M
$10M
$7M
$5M
$2M
$0
2021
2022
2023
2024

Verrica Pharmaceuticals quarterly growth rate over time

YearQ1Q2Q3Q4
2021$12.0M---
2022$431,000$214,000$8.3M$68,000
2023$37,000$182,000$2.9M$2.0M
2024$3.8M$5.2M($1.8M)$344,000

Verrica Pharmaceuticals jobs nearby

Do you work at Verrica Pharmaceuticals?

Is Verrica Pharmaceuticals transparent about its revenue structure?

Verrica Pharmaceuticals financing

Verrica Pharmaceuticals received early financing of $5.0M on 2017-12-22.

SeriesRound sizeDate
Equity$21M02/2018
Equity$5M12/2017

Verrica Pharmaceuticals revenue FAQs

Search for jobs

Zippia gives an in-depth look into the details of Verrica Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Verrica Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Verrica Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Verrica Pharmaceuticals. The data presented on this page does not represent the view of Verrica Pharmaceuticals and its employees or that of Zippia.

Verrica Pharmaceuticals may also be known as or be related to Verrica Pharmaceuticals and Verrica Pharmaceuticals Inc.